Effect of thymosin α1 on lymphocyte subsets in patients with decompensated hepatitis B cirrhosis

Tong Jing; Sun ZhangYu; Yang LiBing; Liang YaLin; Kang YanNan

doi:10.3969/j.issn.1001-5256.2017.11.016

Issue 11

Nov. 2017

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2017 > 33(11): 2132-2135

PDF( 1511 KB)

Effect of thymosin α1 on lymphocyte subsets in patients with decompensated hepatitis B cirrhosis

DOI: 10.3969/j.issn.1001-5256.2017.11.016

Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University

Research funding:

Received Date: 2017-05-17
Published Date: 2017-11-20

Abstract

Abstract

Objective To investigate the change in peripheral blood lymphocyte subsets after the application of thymosin α1 in patients with decompensated hepatitis B cirrhosis, as well as the effect of thymosin α1 on immune function.Methods A total of 106 patients with decompensated hepatitis B cirrhosis who were admitted to The First Affiliated Hospital of Zhengzhou University from October 2015 to December 2016 were enrolled and randomly divided into control group and treatment group, with 53 patients in each group, and 20 healthy subjects who underwent physical examination were enrolled as healthy group.The patients in the control group were given comprehensive medical treatment, and those in the treatment group were given thymosin α1 in addition to the comprehensive medical treatment.Flow cytometry was used to measure peripheral blood CD3+, CD4+, and CD8+cells, CD4+/CD8+ratio, and percentages of CD19 cells and natural killer (NK) cells before treatment and after 12 weeks of treatment.Clinical symptoms, complications, and adverse events were observed.An analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between any two groups;the independent-samples t test or paired t-test was used for comparison between two groups.The chi-square test was used for comparison of categorical data between groups.Results Before treatment, the treatment group and the control group had significantly lower numbers of peripheral blood CD3+, CD4+, and CD8+cells, CD4+/CD8+ratio, and percentages of CD19 cells and NK cells than the healthy group (all P<0.05) .After 12 weeks of treatment, the treatment group showed significant increases in the numbers of CD3+and CD4+cells and CD4+/CD8+ratio (t=7.647, 7.851, and 4.384, all P<0.001) ;compared with the control group, the treatment group had significantly increased numbers of CD3+, CD4+, and CD8+cells (t=5.051, 5.379, and 2.066, all P<0.05) and slightly increaseed CD4+/CD8+ratio and percentages of CD19 cells and NK cells (all P>0.05) .The adverse events during treatment included dizziness and headache, and there was no significant difference in the incidence rate of adverse events between the control group and the treatment group (χ2=1.039, P=0.308) .No patient experienced serious adverse events.Conclusion In patients with decompensated hepatitis B cirrhosis, thymosin α1 can significantly improve the imbalance of lymphocyte subsets and enhance their immune function.
- liver cirrhosis,
- hepatitis B,
- lymphocyte subsets,
- thymosin

FullText(HTML)

References(11)

References

[1]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention andtreatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[2]WANG Y, GAO Q, ZHAN YH.Changes of lymphocyte subsets in liver cirrhosis patients after hepatitis B[J].Chin J Gastroenterol Hepatol, 2015, (4) :452-454. (in Chinese) 王昀, 郜茜, 绽永华.乙型肝炎后肝硬化患者淋巴细胞亚群的变化[J].胃肠病学和肝病学杂志, 2015, (4) :452-454.

[3] DUAN HC, YU XH.Association of Child-Pugh classification with T lymphocyte subsets and NK cell changes in patients with hepatitis B cirrhosis[C].Proceedings of the Seventh National Conference on difficult and severe liver diseases.Beijing:[Publisher unknown], 2013. (in Chinese) 段惠春, 于晓辉.乙型肝炎肝硬化Child-Pugh分级与T淋巴细胞亚群和NK细胞变化的联系[C].第7届全国疑难及重症肝病大会论文集.北京:[出版者不详], 2013.

[4]LI ZJ, LI JS, ZHANG JP, et al.Clinical analysis of thymosin alpha combined with entecavir in the treatment of chronic hepatitis B[J].Chin J Dig, 2015, 35 (2) :127-129. (in Chinese) 李珍杰, 李建生, 张金平, 等.胸腺肽α联合恩替卡韦治疗慢性乙型肝炎的临床分析[J].中华消化杂志, 2015, 35 (2) :127-129.

[5]QIAO R, JIANG FJ, ZHANG Y.Clinical observation of Thymosinα1 on the influence of immune function of lymphocyte in elderly tumor patients[J].Chin J Med Offic, 2015, 43 (7) :707-709. (in Chinese) 乔锐, 姜凤久, 张岩.胸腺肽α1对高龄肿瘤患者淋巴细胞免疫功能的影响[J].临床军医杂志, 2015, 43 (7) :707-709.

[6]CHEN Y, FANG JK, CHEN XZ, et al.Effects of the Treg/Th17cell balance and their associated cytokines in patients with hepatitis B infection[J].Exp Ther Med, 2015, 9 (2) :573-578.

[7]XY DM, DI XZ.Mechanism and research progress of thymosin alpha 1[J].Med J Chin People's Health, 2014, 26 (2) :79-82. (in Chinese) 许冬梅, 邸秀珍.胸腺肽α1的作用机制及研究进展[J].中国民康医学, 2014, 26 (2) :79-82.

[8]ZHAGN HQ, LIU H, ZHOU T, et al.Clinical effect of adefovir dipivoxil combined with thymosinα1 in thd treatment of paitents with HBe Ag positive and no response to lamivudine[J].Int J Virol, 2016, 23 (2) :124-126. (in Chinese) 张华强, 刘海, 周涛, 等.阿德福韦酯联合胸腺肽α1治疗拉米夫定无应答的HBe Ag阳性慢性乙肝的疗效观察[J].国际病毒学杂志, 2016, 23 (2) :124-126.

[9]ZHANG P, HUANG QL, HUA ZC.Research progress of thymosin alpha 1[J].J Southeast Univ:Med Sci Edi, 2013, 32 (3) :344-350. (in Chinese) 张鹏, 黄启来, 华子春.胸腺肽α1的研究进展[J].东南大学学报:医学版, 2013, 32 (3) :344-350.

[10]WANG X, LI W, NIU C, et al.Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study[J].Inflammation, 2011, 34 (3) :198-202.

[11]DANIELLI R, FONSATTI E, CALABRO L, et al.Ann thymosinα1 in melanoma:from the clinical trial setting to the daily practice and beyond[J].Ann N Y Acad Sci, 2012, 1270:8-12.

Relative Articles

[1]	Changxu LI, Xuemin LI, Zhanqiang LIANG, Xibin DUAN, Pengsheng YANG. Application of indocyanine green fluorescence navigation in laparoscopic cholecystectomy after percutaneous transhepatic gallbladder drainage in elderly patients with acute cholecystitis[J]. Journal of Clinical Hepatology, 2023, 39(4): 885-891. doi: 10.3969/j.issn.1001-5256.2023.04.020
[2]	Xuelian PENG, Xiaoqing XU, Qin CAO. Clinical efficacy and safety of Danshu Capsule in treatment of chronic cholecystitis and gallstones[J]. Journal of Clinical Hepatology, 2022, 38(9): 2084-2090. doi: 10.3969/j.issn.1001-5256.2022.09.025
[3]	Zhao GuoPing, Hu JianPing, Wang JiRong, Zhang Ming. Experience in laparoscopic cholecystectomy in treatment of acute calculous cholecystitis: a clinical analysis of 86 cases[J]. Journal of Clinical Hepatology, 2018, 34(3): 517-520. doi: 10.3969/j.issn.1001-5256.2018.03.013
[4]	Xi GuangLi, Dong Hao. Clinical effect of laparoscopic cholecystectomy and prognostic analysis in patients with acute cholecystitis[J]. Journal of Clinical Hepatology, 2018, 34(2): 332-336. doi: 10.3969/j.issn.1001-5256.2018.02.022
[5]	Li ZhenLi, Yang Tian. Diagnosis and surgical treatment of xanthogranulomatous cholecystitis[J]. Journal of Clinical Hepatology, 2017, 33(2): 247-252. doi: 10.3969/j.issn.1001-5256.2017.02.007
[6]	Zhang JingZhe, Yu Kui. Integrated traditional Chinese and Western medicine therapy for acute and chronic cholecystitis[J]. Journal of Clinical Hepatology, 2017, 33(5): 838-842. doi: 10.3969/j.issn.1001-5256.2017.05.009
[7]	Zhao Bin, Qing XiaoSong, Lai Zhao. Clinical effect of laparoscopic versus open cholecystectomy in treatment of patients with portal hypertension complicated by gallstones[J]. Journal of Clinical Hepatology, 2017, 33(5): 888-891. doi: 10.3969/j.issn.1001-5256.2017.05.019
[8]	Tan ZhanHai, Zhu GuangHui, Chen JianRong, Zhou LianMing, Yang Zhi, Zhang JiFa, Zhang XueLi, Dan YuanZhou. Clinical effect of laparoscopic cholecystectomy combined with laparoscopic choledocholithotomy T-tube drainage in treatment of gallbladder and common bile duct stones[J]. Journal of Clinical Hepatology, 2017, 33(5): 883-887. doi: 10.3969/j.issn.1001-5256.2017.05.018
[9]	Zhao HongGuang, Liu Kai, Liu YaHui. The most appropriate timing for selective laparoscopic cholecystectomy after percutaneous transhepatic gallbladder drainage in patients with acute severe cholecystitis aged above 60 years[J]. Journal of Clinical Hepatology, 2017, 33(4): 705-710. doi: 10.3969/j.issn.1001-5256.2017.04.021
[10]	Yang YaLin, Xu ZhiJie. Postoperative infection in laparoscopic cholecystectomy in treatment of acute cholecystitis complicated by choleperitonitis[J]. Journal of Clinical Hepatology, 2017, 33(1): 98-101. doi: 10.3969/j.issn.1001-5256.2017.01.021
[11]	Chen LuBin, Lu: XiaoHui, Guo Xin. Diagnosis,treatment,and outcome of Mirizzi syndrome in the perioperative period of laparoscopic cholecystectomy[J]. Journal of Clinical Hepatology, 2016, 32(7): 1354-1356. doi: 10.3969/j.issn.1001-5256.2016.07.030
[12]	Ran JiangLin, Zhang ShaoMao, Wen Qiang. Effects of laparoscopic retrograde cholecystectomy versus partial cholecystectomy in treatment of complex bile duct diseases: a comparative analysis[J]. Journal of Clinical Hepatology, 2016, 32(4): 750-753. doi: 10.3969/j.issn.1001-5256.2016.04.030
[13]	Zhou JingSong, Pu DongLi, Du ZiYou. Clinical effects of laparoscopy and laparotomy in treatment of gangrenous cholecystitis[J]. Journal of Clinical Hepatology, 2016, 32(5): 914-917. doi: 10.3969/j.issn.1001-5256.2016.05.021
[14]	Fan Hua, Zhang ShengJun. Comparison of efficacy between choledochoscopic gallbladder-preserving cholelithotomy and laparoscopic cholecystectomy in treatment of gallstones: a meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(10): 1665-1670. doi: 10.3969/j.issn.1001-5256.2015.10.026
[15]	Wang WeiHua. Clinical efficacy of percutaneous transhepatic cholecystostomy combined with laparoscopic cholecystectomy for elderly patients with severe calculous cholecystitis[J]. Journal of Clinical Hepatology, 2015, 31(8): 1291-1294. doi: 10.3969/j.issn.1001-5256.2015.08.026
[16]	Liu Chao, Zhang Lei. Clinical efficacy of transumbilical single-port laparoscopic cholecystectomy in treatment of acute cholecystitis[J]. Journal of Clinical Hepatology, 2015, 31(10): 1678-1681. doi: 10.3969/j.issn.1001-5256.2015.10.029
[17]	Dai JunTao, Zhang Ping, Wang Qing, Shen BoMing. Laparoscopic cholecystectomy for acute cholecystitis: clinical analysis of 216 cases[J]. Journal of Clinical Hepatology, 2014, 30(7): 647-649. doi: 10.3969/j.issn.1001-5256.2014.07.018
[18]	Xu DaHua. Evolution and current challenges of laparoscopic cholecystectomy[J]. Journal of Clinical Hepatology, 2013, 29(3): 166-168.
[19]	Yi ZhengHui, Wang DaQing, Chang YingBin. Surgical experience of laparoscopic cholecystectomy in 53 cases of acute cholecystitis [J]. Journal of Clinical Hepatology, 2013, 29(3): 194-195.
[20]	Xi RuGuang, Zhang ShaoGuang, Yang WanHong, Ding YanZhen. The application of intraoperative cholangiography in laparoscopic cholecystectomy[J]. Journal of Clinical Hepatology, 2011, 27(3): 300-301.

Supplements(0)

Cited By

Cited by

Periodical cited type(31)

1.	丁辉，苏雪梅，张蓉. 子宫内膜异位症患者血清GP73和SMAD2表达水平及临床价值研究. 现代检验医学杂志. 2025(01): 122-126+131 .
2.	王慧敏，谭炳芹，王万鹏，吴梦雪. 慢性乙型肝炎病毒感染相关肝病患者血清高尔基体蛋白73水平变化分析. 山东医药. 2025(01): 100-103+108 .
3.	张璨，张欢欢，高飞，任佩佩，罗明阳，闫冬，王馨，王莹莹，曾艳丽. 血清高尔基体蛋白73联合肝脏硬度评估慢性乙型肝炎病毒感染患者肝纤维化进展的价值. 中华实用诊断与治疗杂志. 2024(10): 1013-1018 .
4.	李述美，刘冰，刘仁伟，杨洁. GP73、IL-2R、miR-21预测慢性乙肝患者显著肝纤维化的临床价值. 重庆医学. 2024(23): 3575-3580 .
5.	安薪宇，乔杰，胡灵溪，王荣琦，南月敏. GP73对慢性肝病患者肝纤维化诊断价值的研究. 中华内科杂志. 2023(01): 49-53 .
6.	张航，刘近春. 血清高尔基体蛋白73在非酒精性脂肪性肝病中的作用. 临床肝胆病杂志. 2023(03): 657-662 . 本站查看
7.	马杨青，范海纳，孙鑫，刘成海. 高尔基体蛋白73(GP73)对慢性肝病的诊断价值. 临床肝胆病杂志. 2023(08): 1999-2004 . 本站查看
8.	张欢，雷学忠. 新型血清标志物高尔基体蛋白73在慢性乙型肝炎临床诊治中的研究进展. 华西医学. 2023(08): 1243-1246 .
9.	陈腾千，姜丽华，张生君，蒋义贵，罗佳，胡永敏，尤丽财. 高尔基体蛋白73在非酒精性脂肪性肝病中的应用价值. 黑龙江医学. 2023(17): 2053-2055+2059 .
10.	李雨蓉，姚明解，王杰. 序贯无创检测提高肝纤维化筛查效率. 肝脏. 2023(10): 1146-1149 .
11.	刘燕娜，姚明解，郑素军，陈香梅，刘向祎，胡鹏，欧启水，窦晓光，陈红松，段钟平，侯金林，南月敏，高志良，徐小元，庄辉，鲁凤民. 血清高尔基体蛋白73在慢性肝病患者中的临床应用. 中华肝脏病杂志. 2022(01): 4-8 .
12.	裴倩云，孙颖. 血清免疫球蛋白检验在肝衰竭患者的诊断价值. 系统医学. 2022(15): 103-105+118 .
13.	王鹏飞，刘树红，钱相君，翟相威，文夏杰，姚明解，赵景民，鲁凤民. 血清高尔基体蛋白73对丙型肝炎肝硬化的诊断价值研究. 中华肝脏病杂志. 2022(08): 879-884 .
14.	郑伟明，罗翠转，卢金英，骆晓豪，刘浩，梁栋伟. 血过氧化物酶增殖体激活受体γ与慢性乙型肝炎患者炎症的相关性. 中国肝脏病杂志(电子版). 2022(04): 42-47 .
15.	庄云英，张海燕，曾清芳. 慢性乙型肝炎肝纤维化的无创诊断研究进展. 肝脏. 2021(01): 84-87 .
16.	刘燕娜，姚明解，鲁凤民. 慢性肝病患者中血清高尔基体蛋白73的临床应用. 肝脏. 2021(02): 103-106 .
17.	Application of serum Golgi protein-73 in the management of chronic liver disease. 中华医学杂志英文版. 2021(07): 777-779 .
18.	罗双艳，何颖. 慢性乙肝患者肝脏炎症及纤维化的影响因素及其与血清高尔基体蛋白73的相关性. 医学信息. 2021(15): 5-8 .
19.	高伟，高虹，尹春梅，杨森林，范晓红，刘春亮，李雪卿，贾妮娜. 血清GP73与p62测定对HBV相关慢加急性肝衰竭患者短期预后的预测价值比较. 中华肝脏病杂志. 2021(09): 855-860 .
20.	王一奇，苑喜微，李冬冬，汤玉会，薛宁宁，崔璐瑶，刘领弟，南月敏. 血浆高尔基体蛋白73及相关模型诊断非酒精性脂肪性肝病的研究. 中华肝脏病杂志. 2021(12): 1170-1176 .
21.	张春林. 患儿脓毒症继发肝损伤的危险因素及血清高尔基体跨膜糖蛋白73、微小RNA-122a水平变化. 中国临床医生杂志. 2020(02): 236-238 .
22.	刘沁雨，常越，张青，丁玉平，李海. 高尔基体蛋白73对抗病毒治疗慢性乙型肝炎患者代偿期肝硬化的诊断价值. 解放军医药杂志. 2020(03): 86-91 .
23.	翟相威，刘树红，姚明解，钱相君，文夏杰，许强，赵景民，鲁凤民. 基于血清高尔基体蛋白73的代偿期乙型肝炎肝硬化无创诊断模型的建立及初步应用. 中华肝脏病杂志. 2020(01): 47-52 .
24.	范旭，单珊，刘立伟，贾继东. 血清高尔基糖蛋白73优于APRI、FIB-4对慢性HBV感染患者显著纤维化的诊断. 现代消化及介入诊疗. 2020(04): 529-532 .
25.	范旭，单珊，刘立伟，贾继东. 血清高尔基体跨膜糖73蛋白及其他生物标志物联合检测在AFP阴性小肝癌诊断中的意义. 现代消化及介入诊疗. 2020(04): 435-439+443 .
26.	刘沁雨，常越，张文，张青，卢诚震，李海. GP73预测慢性乙型肝炎患者肝硬化进展研究. 武警医学. 2020(04): 317-323 .
27.	马玲玉，甄一宁，罗云萍，段昭君. gp73在小鼠肝纤维化肝组织中的表达及机制. 基础医学与临床. 2020(06): 771-776 .
28.	刘沁雨，常越，张青，丁玉平，李海. 血清GP73与PYGO2对已长期抗病毒治疗慢性乙型肝炎肝硬化的诊断价值. 山东医药. 2020(29): 64-66 .
29.	李佳娜，郑瑞琦，李娜，胡玉琳. 高尔基体蛋白73的生物学特征及在肝纤维化和肝硬化中的诊断价值. 临床肝胆病杂志. 2019(06): 1361-1364 . 本站查看
30.	王春艳，纪冬，马丽君，陈松海，王晶晶，邵清，陈国凤，韩萍. 慢性乙型肝炎患者血清高尔基体蛋白73及其与肝脏炎症及纤维化的相关性. 解放军医学杂志. 2019(06): 503-507 .
31.	宋莹，李世朋，焦伟伟. 血清HMGB1、TGFβ1及GP73检测对脓毒症并发肝损伤预后的评估价值. 分子诊断与治疗杂志. 2019(06): 457-461 .

Other cited types(12)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2218) PDF downloads(425)

Effect of thymosin α1 on lymphocyte subsets in patients with decompensated hepatitis B cirrhosis

DOI: 10.3969/j.issn.1001-5256.2017.11.016